Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 3/20 | 0.40 |
| ▸ | GIPR | P48546 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653025 | 0.88 | PPARG (0.56) | PPARGGCGRTP53MAPT | |
| SCHEMBL2652239 | 0.87 | GCGR (0.40) | PPARGKMT2AMEN1GCGRGIPR | |
| SCHEMBL2652296 | 0.77 | PPARG (0.49) | PPARGGCGR | |
| SCHEMBL2651740 | 0.76 | PPARG (0.42) | PPARGGCGR | |
| SCHEMBL2654051 | 0.76 | PPARG (0.55) | PPARGKMT2AMEN1TBXA2RGCGR | |
| SCHEMBL2661770 | 0.75 | PPARG (0.52) | PPARGGCGRGIPR | |
| SCHEMBL2652185 | 0.71 | GCGR (0.60) | GCGRGIPR | |
| SCHEMBL9256074 | 0.71 | ITGB3 (0.54) | PPARGTBXA2R | |
| Hydrochloric Acid SCHEMBL9254502 | 0.70 | ITGB3 (0.53) | PPARGTBXA2R | |
| SCHEMBL2651576 | 0.70 | EGLN1 (0.48) | PPARGGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | PPARG 122/4885KMT2A 3911/4885MEN1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.